OXOLIFE

Executive Summary

OXOLIFE is a clinical-stage biotechnology company headquartered in Barcelona, Spain, dedicated to developing first-in-class, non-hormonal oral therapies for female infertility. Its lead asset, OXO-001, is designed to directly enhance embryo implantation by targeting the endometrium, thereby improving pregnancy and live birth rates in women undergoing assisted reproductive technologies (ART). Additionally, OXOLIFE is exploring OXO-001 for infertility associated with Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women worldwide. The company's approach addresses a significant unmet medical need, as current fertility treatments often rely on hormonal stimulation and have limited success in improving implantation rates. By offering a novel mechanism of action that avoids systemic hormonal effects, OXO-001 has the potential to become a cornerstone therapy in reproductive medicine. The company is privately held and has not disclosed detailed financial or valuation data. However, its progression into clinical trials underscores the promise of its platform. OXOLIFE's focus on a high-demand therapeutic area and its differentiated oral, non-hormonal strategy position it as an attractive candidate for partnerships or further investment. Key upcoming milestones include clinical data readouts and potential regulatory interactions, which will be critical in validating OXO-001's efficacy and safety. Investors and collaborators should monitor progress closely, as positive results could significantly de-risk the asset and open substantial commercial opportunities in the fertility market.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line results for OXO-001 in assisted reproduction60% success
• Q2 2027Initiation of Phase 2 trial for OXO-001 in PCOS-associated infertility70% success
• H1 2027Announcement of strategic partnership or licensing deal40% success